Search results for "connective tissue disease"

showing 10 items of 874 documents

Synthesis and biological evaluation of a novel MUC1 glycopeptide conjugate vaccine candidate comprising a 4’-deoxy-4’-fluoro-Thomsen–Friedenreich epi…

2015

The development of selective anticancer vaccines that provide enhanced protection against tumor recurrence and metastasis has been the subject of intense research in the scientific community. The tumor-associated glycoprotein MUC1 represents a well-established target for cancer immunotherapy and has been used for the construction of various synthetic vaccine candidates. However, many of these vaccine prototypes suffer from an inherent low immunogenicity and are susceptible to rapid in vivo degradation. To overcome these drawbacks, novel fluorinated MUC1 glycopeptide-BSA/TTox conjugate vaccines have been prepared. Immunization of mice with the 4’F-TF-MUC1-TTox conjugate resulted in strong im…

Synthetic vaccinemedicine.medical_treatmentMUC1Full Research PaperEpitopelcsh:QD241-441Immune systemCancer immunotherapylcsh:Organic chemistryConjugate vaccinemedicineskin and connective tissue diseaseslcsh:Scienceneoplasmsfluorinated carbohydratescancer immunotherapyChemistryImmunogenicityOrganic ChemistryTACAdigestive system diseasesglycoconjugatesChemistryImmunizationImmunologyCancer researchlcsh:QConjugateBeilstein Journal of Organic Chemistry
researchProduct

Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies.

2001

The induction of anti-DNA autoantibodies in systemic lupus erythematosus (SLE) patients is problematic because mammalian DNA is poorly immunogenic at best. Here we demonstrate a chain of connected antibodies in SLE patient sera that could account for the induction of anti-DNA antibody, and possibly for some of the pathogenic features of SLE. We now report that SLE patients, in addition to anti-DNA, produce antibodies to the carboxy-terminal domain of the tumour suppressor molecule p53; this p53 domain recognizes damaged DNA. Hence, these anti-p53 antibodies could mimic damaged DNA immunologically. Indeed, SLE sera do contain anti-idiotypic antibodies to a prototypic anti-p53 antibody. Moreo…

Systemic diseaseAnti-nuclear antibodyImmunologyBiologymedicine.disease_causeProtein Structure SecondaryAutoimmunityImmunoglobulin Idiotypesimmune system diseasesmedicineImmunology and AllergyHumansLupus Erythematosus Systemicskin and connective tissue diseasesAutoantibodiesAutoimmune diseaseLupus erythematosusMolecular MimicryAutoantibodymedicine.diseaseDNA-Binding ProteinsMolecular mimicryAntibodies AntinuclearImmunologyCancer researchbiology.proteinAntibodyTumor Suppressor Protein p53PeptidesJournal of autoimmunity
researchProduct

Autoreactivity to mouse C1q in a murine model of SLE.

1995

A large proportion of systemic lupus erythematosus (SLE) patients develop glomerulonephritis, coincident with the appearance of autoantibodies to C1q, the Fc-recognizing collagen-like subcomponent of the first component of complement, C1. The MRL/lpr/lpr mouse is an established model for SLE, developing both antinuclear and anti-type II collagen autoantibodies, and rheumatoid factors(s), exhibiting reduced complement levels and later on developing glomerulonephritis and often arthritis. We report here an age-dependent decrease in serum C1q levels coincident with the development of IgG2b autoantibodies reactive with mouse C1q in MRL/lpr/lpr mice. Unlike IgG2b, although high levels of IgM, Ig…

Systemic diseaseImmunologyArthritischemical and pharmacologic phenomenaEnzyme-Linked Immunosorbent Assayurologic and male genital diseasesmedicine.disease_causeAutoimmunityMiceRheumatologyimmune system diseasesImmunology and AllergyMedicineAnimalsLupus Erythematosus Systemicskin and connective tissue diseasesAutoantibodiesLupus erythematosusbusiness.industryComplement C1qAutoantibodyGlomerulonephritismedicine.diseaseConnective tissue diseaseLupus NephritisDisease Models AnimalImmunologybusinessAnti-SSA/Ro autoantibodiesRheumatology international
researchProduct

Analysis of Epitope Spreading over an Eleven-year Period in a Patient with Systemic Lupus Erythematosus: CASE REPORT

1998

During a period of more than eleven years serum samples of a patient with Systemic Lupus Erythematosus were collected and analyzed for anti-nuclear autoantibodies. High titer of anti-La/SS-B were detectable in all serum samples. The La/SS-B epitopes remained constant. Besides anti-La/SS-B antibodies all serum samples contained traces of anti-Ro/SS-A including anti-Ro52 and anti-Ro60 antibodies. During disease flares anti-Ro/SS A antibodies were upregulated and anti-dsDNA antibodies appeared, thus supporting the concept of an antigen driven intermolecular epitope spreading to Ro/SS-A and dsDNA.

Systemic diseaseLupus erythematosusAnti-nuclear antibodybiologybusiness.industryImmunologyGeneral Medicinemedicine.diseasemedicine.disease_causeEpitopeAutoimmunityEpitope mappingRheumatologyAntigenImmunologymedicinebiology.proteinImmunology and AllergyAntibodyskin and connective tissue diseasesbusinessScandinavian Journal of Rheumatology
researchProduct

T-cell hyperreactivity of NZB mice against H-2 identical cells

1983

NZB mice serve as a model for human systemic lupus erythematodes. T-cell abnormalities in this strain have previously been described. In this paper the cytotoxic T lymphocyte precursor (CTL-p) frequencies of NZB mice against H-2 allogeneic and H-2 syngeneic cells are investigated and compared with those of the normal strain BALB/c. The CTL-p frequency in NZB lymphocytes against H-2 allogeneic cells equals that in normal mouse strains (i.e. 1/7500). The NZB anti BALB/c response is in the same order of magnitude. No corresponding BALB/c anti NZB response was elicited. The results suggest abnormally high sensitivity of NZB CTL-p to helper signals.

T cellImmunologychemical and pharmacologic phenomenaurologic and male genital diseasesMiceRheumatologyimmune system diseasesAnimalsLupus Erythematosus SystemicImmunology and AllergyCytotoxic T cellMedicineskin and connective tissue diseasesMice Inbred BALB CMice Inbred NZBStrain (chemistry)business.industrySystemic lupusT-Lymphocytes Helper-InducerDisease Models AnimalCTL*medicine.anatomical_structureCytotoxic T-lymphocyte precursor frequencyImmunologybusinessT-Lymphocytes CytotoxicRheumatology International
researchProduct

The significance of FNAC in diagnosing differentiated thyroid cancer and the discrepancy between theory and practice - a multi-centre study.

2020

 After non-invasive diagnostic modalities high risk thyroid nodules are investigated with fine needle aspiration cytology in order to find the right surgical strategy for suspected malignancies. Despite the clear recommendation by the European and the American associations (ETA, ATA) its clinical value is doubted and its importance in clinical practice not fully clarified. A multicentric study of 119 patients with differentiated thyroid cancer operated on in 24 surgical departments was conducted. The aim was not only to evaluate the use of FNAC as a diagnostic tool, but also to investigate its diagnostic validity and compare it with that of other, non-invasive diagnostic methods. FNAC was u…

Thyroid nodulesAdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentBiopsy Fine-NeedleScintigraphyCohort StudiesDiagnosis DifferentialYoung AdultBiopsymedicineHumansRadiology Nuclear Medicine and imagingThyroid Neoplasmsskin and connective tissue diseasesThyroid cancerAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industryRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseasebody regionsLymphadenectomyFemaleRadiologyUltrasonographybusinessCohort studyNuklearmedizin. Nuclear medicine
researchProduct

Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy.

2010

Norbert Pfeiffer1, Maria-Luise Scherzer2, Hubert Maier3, Sonja Schoelzel4, Mark C Jasek5, Jeanette A Stewart6, William C Stewart6 On behalf of the DuoTravMED study group1Johannes Gutenberg-Universität Mainz, Mainz, Germany; 2Regenstauf, Germany; 3Gerolzhofen, Germany; 4Institutes of Molecular Medicine, University of Freiburg, Department of Surgery, Freiburg, Germany; 5Alcon Laboratories, Inc., Fort Worth, TX, USA; 6PRN Pharmaceutical Research Network, LLC, Charleston, SC, USAPurpose: To assess the safety and efficacy of changing to the travoprost/timolol fixed combination (TTFC) from other mono- or adjunctive therapies.Patients and methods: A prospective, open-label, observational …

Timolol maleatesafetyIntraocular pressuremedicine.medical_specialtyprimary open-angle glaucomagenetic structuresbusiness.industrytravoprost/timolol fixed combinationefficacyTimololOcular hypertensionClinical Ophthalmologymedicine.diseaseeye diseasesOphthalmologyOphthalmologymedicineocular hypertensionTravoprostsense organsskin and connective tissue diseasesbusinessmedicine.drugOriginal Researchintraocular pressureClinical ophthalmology (Auckland, N.Z.)
researchProduct

Development, Differentiation, and Diversity of Innate Lymphoid Cells

2014

Recent years have witnessed the discovery of an unprecedented complexity in innate lymphocyte lineages, now collectively referred to as innate lymphoid cells (ILCs). ILCs are preferentially located at barrier surfaces and are important for protection against pathogens and for the maintenance of organ homeostasis. Inappropriate activation of ILCs has been linked to the pathogenesis of inflammatory and autoimmune disorders. Recent evidence suggests that ILCs can be grouped into two separate lineages, cytotoxic ILCs represented by conventional natural killer (cNK) cells and cytokine-producing helper-like ILCs (i.e., ILC1s, ILC2s, ILC3s). We will focus here on current work in humans and mice th…

Transcription GeneticLymphocyteCellular differentiationImmunologyBiologyArticleTight Junctions03 medical and health sciencesMice0302 clinical medicinemedicineTranscriptional regulationCytotoxic T cellImmunology and AllergyAnimalsHumansCell Lineageskin and connective tissue diseases030304 developmental biologyRegulation of gene expression0303 health sciencesStem CellsInnate lymphoid cellCell DifferentiationT-Lymphocytes Helper-InducerImmunity InnateKiller Cells Naturalbody regionsMulticellular organismmedicine.anatomical_structureInfectious DiseasesGene Expression RegulationImmunologyCytokinesStem cell030215 immunologySignal TransductionImmunity
researchProduct

Regulation ofMUC1Expression in Human Mammary Cell Lines by the c-ErbB2 and Ras Signaling Pathways

2001

The MUC1 protein is a highly O-glycosylated transmembrane molecule that is expressed at the luminal surface of most glandular epithelial cells and is upregulated in carcinomas. Here, we report the effect of the activation of the c-ErbB2 --Ras pathway on the expression of the MUC1 gene in the nontumorigenic mammary cell lines MTSV1-7 and HB2 and in the malignant cell lines T47D and ZR75. Endogenous levels of MUC1 mRNA and protein in HB2 clones permanently overexpressing c-ErbB2 or V12-H-Ras were markedly reduced compared with levels in the parental cell lines. Furthermore, in transient transfection assays, the transcription of a CAT reporter construct driven by the MUC1 promoter was inhibite…

Transcription GeneticReceptor ErbB-2Recombinant Fusion ProteinsMutantDown-RegulationBreast NeoplasmsBiologyTransfectionCell LineWortmanninPhosphatidylinositol 3-Kinaseschemistry.chemical_compoundGenes ReporterTranscription (biology)Anti-apoptotic Ras signalling cascadeTumor Cells CulturedGeneticsHumansBreastPromoter Regions Geneticskin and connective tissue diseasesneoplasmsMolecular BiologyMUC1Phosphoinositide-3 Kinase InhibitorsOncogeneMucin-1Cell BiologyGeneral MedicineGenes erbB-2Molecular biologyTransmembrane proteinCell biologyAndrostadienesGenes rasGene Expression Regulationchemistryras ProteinsFemaleSignal transductionWortmanninSignal TransductionDNA and Cell Biology
researchProduct

Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol.

2013

Many of the cardiovascular protective effects of resveratrol are attributable to an enhanced production of nitric oxide (NO) by the endothelial NO synthase (eNOS). Resveratrol has been shown to enhance eNOS gene expression as well as eNOS enzymatic activity. The aim of the present study was to analyze the molecular mechanisms of eNOS transcriptional activation by resveratrol. Treatment of human EA.hy 926 endothelial cells with resveratrol led to a concentration-dependent upregulation of eNOS expression. In luciferase reporter gene assay, resveratrol enhanced the activity of human eNOS promoter fragments (3500, 1600, 633 and 263bp in length, respectively), indicating that the proximal promot…

Transcriptional ActivationCancer Researchendocrine system diseasesNitric Oxide Synthase Type IIIPhysiologyClinical BiochemistryFOXO1ResveratrolBiochemistryCell LineTransactivationchemistry.chemical_compoundSirtuin 1EnosStilbenesHumansRNA Small Interferingskin and connective tissue diseasesPromoter Regions GeneticTranscription factorGene knockdownAnalysis of VariancebiologySirtuin 1Chemistryorganic chemicalsfood and beveragesForkhead Transcription Factorsbiology.organism_classificationMolecular biologyUp-RegulationNitric oxide synthaseResveratrolGene Knockdown Techniquesbiology.proteinhormones hormone substitutes and hormone antagonistsNitric oxide : biology and chemistry
researchProduct